SOPHiA GENETICS (NASDAQ:SOPH) Insider Manuela Valente Sells 4,241 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Manuela Valente sold 4,241 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $5.05, for a total value of $21,417.05. Following the completion of the transaction, the insider owned 210,450 shares of the company’s stock, valued at approximately $1,062,772.50. The trade was a 1.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Manuela Valente also recently made the following trade(s):

• On Monday, April 20th, Manuela Valente sold 380 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.20, for a total value of $1,976.00.
• On Wednesday, April 8th, Manuela Valente sold 3,824 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total value of $18,546.40.

SOPHiA GENETICS Price Performance

SOPH opened at $5.44 on Wednesday. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. The company has a market cap of $456.36 million, a price-to-earnings ratio of -10.46 and a beta of 0.96. The stock has a fifty day simple moving average of $5.13 and a two-hundred day simple moving average of $4.97. SOPHiA GENETICS SA has a 12-month low of $2.92 and a 12-month high of $6.30.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The business had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Institutional Trading of SOPHiA GENETICS

Institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC bought a new stake in SOPHiA GENETICS during the 3rd quarter valued at about $49,000. Perkins Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at approximately $49,000. First Dallas Securities Inc. bought a new stake in shares of SOPHiA GENETICS during the first quarter valued at approximately $50,000. Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at approximately $54,000. Finally, XTX Topco Ltd purchased a new position in SOPHiA GENETICS in the 4th quarter worth approximately $55,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SOPH has been the subject of a number of analyst reports. BTIG Research reaffirmed a “buy” rating and set a $8.00 target price on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $7.50.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: The insider sales were mostly routine, pre-planned transactions tied to equity-award vesting and tax withholding, which suggests they may not signal a fundamental change in the business or management’s outlook.
• Neutral Sentiment: Multiple executives and directors, including Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, and others, reported sales in the same period, increasing investor focus on insider activity.
• Negative Sentiment: Even if planned, the cluster of insider share sales can create pressure on sentiment because it may be interpreted as reduced confidence or excess supply in the stock near term.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.